5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"

On July 4^th, the 2024 International Pharmaceutical Services Industry Innovation and Development Conference, along with the 9^th Summit for China Pharmaceutical R&D Innovation, was grandly held at the Xiongan Convention and Exhibition Center. At the conference, the highly anticipated "2024 China Pharmaceutical R&D Strength Ranking" was announced. Shanghai Medicilon Inc. (Medicilon) stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.

top 20 cro.webp

About the Top 20 Chinese R&D CRO Enterprises in 2024

The "2024 China Pharmaceutical R&D Strength Ranking" is selected by the Organizing Committee of the China Pharmaceutical R&D Innovation Summit and the Expert Committee of the 2024 China Pharmaceutical R&D Strength Ranking. It aims to uncover and drive innovative forces in pharmaceutical R&D, encourage and recognize enterprises making significant contributions to pharmaceutical R&D, and further enhance the industry's focus on innovation in pharmaceutical R&D. The "Top 20 Chinese R&D CRO Enterprises in 2024" list is strictly evaluated based on ten criteria such as annual total revenue, annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, personnel size, personnel size growth, brand recognition, and leadership in specific subfields. These criteria represent the highest standards in the Chinese pharmaceutical CRO industry.

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客